CervoMed locks in neflamapimod exclusivity through 2042 with pure DLB patent strategy

Edited by Robert McTiernan··3 min read

Boston-based CervoMed Inc. (Nasdaq: CRVO) received a notice of allowance from the USPTO for a method-of-treatment patent protecting the use of neflamapimod in patients with dementia with Lewy bodies who lack substantial Alzheimer’s disease-like tau pathology — a population defined as “pure DLB”. The patent is expected to provide US protection through 2042, with the potential for additional exclusivity through patent term extension.

The allowance is strategically important because it protects a biomarker-defined patient population rather than simply the drug itself. The claims cover DLB patients identified through plasma pTau testing or brain imaging as having little or no coexisting AD-type tau pathology, a subgroup often referred to as “pure DLB.” The approach mirrors the patient-enrichment strategy used in CervoMed’s Phase IIb RewinD-LB study and could strengthen the company’s position as it seeks a partner to fund a Phase III program.

No therapies are currently approved specifically for DLB in either the US or EU. While the commercial opportunity remains uncertain, the patent provides CervoMed with a potentially defensible exclusivity position in a disease area with significant unmet need.

Neflamapimod is an oral inhibitor of p38 mitogen-activated protein kinase alpha (p38α MAPK), an enzyme implicated in neuroinflammation and synaptic dysfunction. The company believes inhibition of this pathway may address upstream disease mechanisms associated with alpha-synuclein-driven neurodegeneration.

CervoMed completed the RewinD-LB trial in patients enriched for those without significant AD co-pathology and reported reaching alignment with the US FDA in late 2025 on a potential registration pathway. However, the company has disclosed limited details on the underlying efficacy data, leaving the strength of the clinical package as the key outstanding question for investors and prospective partners. Initiation of a Phase III trial remains dependent on securing external funding or a development partner.

The AllSci BriefSystematic R&D and deal news. Daily.

The patent’s value ultimately rests on whether the biomarker-defined subgroup can support a successful registrational program. By linking its intellectual property strategy to a diagnostically identifiable patient population, CervoMed has aligned its exclusivity position with its clinical development approach. Potential partners will likely focus less on the patent itself than on whether the RewinD-LB data demonstrate a meaningful treatment effect in that subgroup.

Beyond DLB, CervoMed is evaluating neflamapimod in additional neurodegenerative indications. Interim biomarker data from a Phase II study in nonfluent variant primary progressive aphasia are expected in early Q4 2026, while a Phase IIa trial in amyotrophic lateral sclerosis is expected to begin dosing patients in Q4 2026.

Competition in DLB remains limited. Current treatment relies largely on off-label symptomatic therapies such as acetylcholinesterase inhibitors and antipsychotics, none of which are approved specifically for the disease. Several companies are pursuing therapies targeting alpha-synuclein pathology, but no late-stage disease-modifying therapy has yet emerged as a clear leader in DLB.

The patent allowance strengthens CervoMed’s intellectual property position and extends a potential exclusivity runway into the next decade. Whether that translates into a partnership capable of advancing neflamapimod into Phase III development will depend largely on the quality of the RewinD-LB data and the company’s ability to demonstrate a clinically meaningful benefit in the biomarker-selected patient population.

This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/